ASCENDIS PHARMA A/S - ADR (ASND) Stock Price, Forecast & Analysis
USA - NASDAQ:ASND - US04351P1012 - ADR
ASND Key Statistics, Chart & Performance
The current stock price of ASND is 217.13 USD. In the past month the price increased by 8.25%. In the past year, price increased by 67.27%.
ASND Latest News, Press Relases and Analysis
ASND Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.75 | 413.15B | ||
| AMGN | AMGEN INC | 15.73 | 185.19B | ||
| GILD | GILEAD SCIENCES INC | 15.53 | 157.81B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.09 | 111.66B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.12 | 76.88B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 906.47 | 60.60B | ||
| INSM | INSMED INC | N/A | 42.62B | ||
| NTRA | NATERA INC | N/A | 29.32B | ||
| BIIB | BIOGEN INC | 10.09 | 24.75B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.06 | 21.56B | ||
| INCY | INCYTE CORP | 16.18 | 20.29B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 33.17 | 13.75B |
Related stock screener links
About ASND
Company Profile
Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. The firm produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The firm operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).
Company Info
ASCENDIS PHARMA A/S - ADR
Tuborg Boulevard 12
Hellerup 2900 DK
CEO: Jan Moller Mikkelsen
Employees: 1017
Phone: 4570222244
ASCENDIS PHARMA A/S - ADR / ASND FAQ
Can you describe the business of ASCENDIS PHARMA A/S - ADR?
Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. The firm produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The firm operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).
What is the stock price of ASCENDIS PHARMA A/S - ADR today?
The current stock price of ASND is 217.13 USD. The price increased by 0.26% in the last trading session.
Does ASND stock pay dividends?
ASND does not pay a dividend.
What is the ChartMill rating of ASCENDIS PHARMA A/S - ADR stock?
ASND has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
On which exchange is ASND stock listed?
ASND stock is listed on the Nasdaq exchange.
What sector and industry does ASCENDIS PHARMA A/S - ADR belong to?
ASCENDIS PHARMA A/S - ADR (ASND) operates in the Health Care sector and the Biotechnology industry.
What is ASCENDIS PHARMA A/S - ADR worth?
ASCENDIS PHARMA A/S - ADR (ASND) has a market capitalization of 13.14B USD. This makes ASND a Large Cap stock.
ASND Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to ASND. When comparing the yearly performance of all stocks, ASND is one of the better performing stocks in the market, outperforming 92.29% of all stocks.
ASND Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ASND. ASND may be in some trouble as it scores bad on both profitability and health.
ASND Financial Highlights
Over the last trailing twelve months ASND reported a non-GAAP Earnings per Share(EPS) of -4.47. The EPS increased by 48.33% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -20.17% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ASND Forecast & Estimates
23 analysts have analysed ASND and the average price target is 266.83 USD. This implies a price increase of 22.89% is expected in the next year compared to the current price of 217.13.
For the next year, analysts expect an EPS growth of 63.46% and a revenue growth 134.79% for ASND